Table 2.
Proportion of patients with virological cure (negative nasopharyngeal PCR) by day, in COVID-19 patients treated with hydroxychloroquine and in COVID-19 control patients.
| Day3 post inclusion |
Day4 post inclusion |
Day5 post inclusion |
Day6 post inclusion |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of negative patients/total number of patients | % | p-value | Number of negative patients/total number of patients | % | p-value | Number of negative patients/total number of patients | % | p-value | Number of negative patients/total number of patients | % | p-value | |
| Hydroxychloroquine treated patients (N=20) | 10/20 | 50.0 | 0.005 | 12/20 | 60.0 | 0.04 | 13/20 | 65.0 | 0.006 | 14/20 | 70.0 | 0.001 |
| Control patients (N=16) | 1/16 | 6.3 | 4/16 | 25.0 | 3/16 | 18.8 | 2/16 | 12.5 | ||||
acontrol patients from centers other than Marseille did not undergo daily sampling, but were sampled every other day in most cases, they were considered positive for PCR when actually positive the day(s) before and the day(s) after the day(s) with missing data.